TrialJournal of the American Society of Nephrology : JASN2026

Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.

Alexis Hofherr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.